The Claim
Co-treatment with a 15-PGDH inhibitor and semaglutide in obese mice enhances muscle strength recovery after injury by 30–40% compared to semaglutide alone, without compromising the drug’s fat-loss or glucose-improving effects.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice, combining a 15-PGDH inhibitor with semaglutide increases muscle strength recovery after injury by 30–40% compared to semaglutide alone, while maintaining the same reductions in body fat and improvements in glucose levels.
See the scientific wording
Co-treatment with a 15-PGDH inhibitor and semaglutide in obese mice enhances muscle strength recovery after injury by 30–40% compared to semaglutide alone, without compromising the drug’s fat-loss or glucose-improving effects.
When a drug that reduces appetite is given, it lowers nutrient levels in muscle tissue, which puts muscle repair cells into a dormant state and slows healing after injury. Another drug blocks the enzyme that breaks down a signaling molecule called PGE2, causing PGE2 to build up. This molecule activates receptors on the muscle repair cells, triggering a chain reaction inside them that wakes them up and makes them multiply. More repair cells lead to faster formation of new muscle fibers, restoring strength without affecting fat loss or blood sugar.
What the research says
1 studyWhen obese mice on semaglutide get injured, they heal slowly—but adding another drug (15-PGDH inhibitor) helps their muscles recover much faster, by about one-third more, without making them lose less fat or worsen their blood sugar.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.